1. P311 Intensive dried blood spot sampling shows a higher drug exposure throughout the first 24 weeks of therapy in ustekinumab-treated Crohn's disease patients achieving endoscopic remission. (27th May 2021) Authors: Van den Berghe, N; Verstockt, B; Ballet, V; Gils, A; Sabino, J; Ferrante, M; Vermeire, S; Declerck, P; Thomas, D Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S338 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P464 Vedolizumab concentrations in colonic mucosal tissue of ulcerative colitis patients inversely correlate with the severity of inflammation. (15th January 2020) Authors: Van den Berghe, N; Verstockt, B; Gils, A; Ferrante, M; Vermeire, S; Thomas, D Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S411 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P478 Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients. (25th January 2019) Authors: Van den Berghe, N; Verstockt, B; Tops, S; Ferrante, M; Vermeire, S; Gils, A Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S351 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗